Happy 9th Birthday Solentim
What a year this one has been!
Aaron Figg, Director
"We strive to support our customers in developing more and better biopharmaceuticals to treat patients. By continually innovating to create unique and unrivalled technologies, we bring practical solutions to the problems of the drug discovery and development process"
Optimising workflows
We provide solutions for customers working across cell line development:
Novel Biotherapeutics
Isolate, screen and characterise attributes for clones producing novel recombinant proteins e.g. monoclonal antibodies or therapeutic proteins for rare diseases
Biosimilars and Biobetters
Generate stable cell lines to create equivalents (Biosimilars) or improved versions (Biobetters) of existing blockbuster therapeutic antibodies for which the patent has, or will shortly, expire
Gene Therapy & CAR-T
Develop new, stable, producer cell lines manufacturing viruses to subsequently infect target cells of patients
Gene Editing & Cell Engineering
Optimise your drug discovery process using targeted gene editing to create stable cell lines as cellular reagents, for use in target validation, functional genomics and disease modelling
VIEW OUR WEBINAR
"How a Top-5 Pharma Doubled the Speed of Cell Line Development"
Latest News
Solentim in the Press: “Fast-Tracking Cell-Line Development”, BioCompare
“Protein pharmaceuticals represent a multibillion-dollar market, but deciphering the most suitable biotherapeutic-producing cell lines is a substantial manufacturing bottleneck”, writes Lauren Tanabe for a recent article published by BioCompare. CHO
Happy 9th Birthday Solentim – and what a year this one has been!
Dave Elverd, Ian Taylor, Aaron Figg, Sky Jiang Solentim is nine years old, and what better way to mark this landmark than to take a look
Solentim, along with partner ATUM, will present at the forthcoming Cell Line Development and Engineering US Conference
Solentim, a global leader in cell line development instrumentation, will be speaking and exhibiting at the Cell Line Development and Engineering Conference US, which returns to San Francisco later this
Removal of fluorescence screening of clones in cell line development: a paradigm shift
Dr Ian Taylor, Chief Commercial Officer, Solentim, blogs on his views following the recent ESACT conference in Copenhagen. Having just returned from ESACT in Copenhagen, I was impressed once again
Solentim will be exhibiting at Hanson Wades’s 5th Precision CRISPR Genome Editing Congress in Boston
Solentim, a global leader in cell line development instrumentation is pleased to announce it will be attending and exhibiting at the 5th Precision CRISPR Genome Editing Congress, 21st-23rd May, in Boston,
Solentim, along with collaborator Janssen, will be speaking and exhibiting at the 8th Annual Cell Line Development and Engineering Asia Conference
Solentim, a global leader in cell line development instrumentation, will be speaking and exhibiting at the 8thAnnual Cell Line Development and Engineering Asia conference, 14th-16thMay 2019, in Shanghai. Experts from
Solentim and SAL Scientific announce partnership for novel growth supplements in cell line development
Solentim, the global leader in cell line development (CLD) imaging instrumentation, and SAL Scientific, a leading provider of growth enhancing animal-free cell culture reagents, are pleased to announce a new strategic
Postcard from BPI Europe in Vienna – Highlights of the Cell Line Development Stream
This annual meeting in early Spring is always a good forum for major new product and technology announcements. In previous years, discussions often mainly centred around assurance of clonality and
Conference News Item: Solentim presenting two posters at ESACT 2019
Solentim, a global leader in cell line development instrumentation, is pleased to announce it will be attending the 26th ESACT Meeting, 5th – 8th May 2019 in Copenhagen, Denmark. Experts
Valitacell and Solentim secure €3.5m funding to optimise the development of new biologics and cell therapies
Left to right: Ian Taylor, CCO, Solentim; Jerry Clifford, COO, Valitacell; Aaron Figg, Director, Solentim; Carolanne Doherty, Sales & Marketing Manager, Valitcell A consortium, consisting of